secwatch.observer — SEC 8-K summary
======================================

Issuer:     NKGen Biotech, Inc. (—)
CIK:        0001845459
Form:       8-K
Filed at:   2023-10-05T23:59:59+00:00
Accession:  0001104659-23-107256
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 2.01, 9.01, 3.02, 4.01, 3.03, 5.01, 5.02, 5.03, 5.05, 5.06, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

NKGen Biotech closes de-SPAC merger with Graf; 21.9M shares outstanding, ~$21M gross proceeds
--------------------------------------------------------------------------------

- Merger closed Sept 29, 2023; former Graf renamed NKGen Biotech; post-closing shares outstanding 21,888,976.
- Legacy NKGen shareholders received 15.6M shares at 0.408 exchange ratio; Graf stockholders redeemed 3.39M shares for $36.2M.
- Company received ~$21.0M in gross proceeds from trust ($0.8M) and warrant/SPA transactions ($20.2M).
- Forward purchase agreements: Meteora (up to 2.5M shares), Sandia (up to 471k shares), Polar (up to 1M shares) as partial financing.
- Warrant subscription agreements: aggregate ~10.2M warrants at $1.00 per warrant sold to investors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1845459/000110465923107256/0001104659-23-107256-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1845459/000110465923107256/tm2327139d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-107256

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer